lirilumab: Clinical Trials

6 completed, 1 recruiting, 1 terminated. 8 Phase 1, 4 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	8	Completed 6, Recruiting 1, Terminated 1
Phase 2	4	Completed 2, Recruiting 1, Terminated 1

Follow lirilumab: new trials by email Literature Review of lirilumab trials Research Report on lirilumab

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Nivolumab, Nivolumab/Lirilumab - Bladder Cancer	Phase 1	Completed	PrECOG, LLC.	43	2019-03-22	2024-09-19
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) Epacadostat, Nivolumab, Ipilimumab - Solid Tumors	Phase 1 / Phase 2	Terminated	Incyte Corporation	11	2018-03-21	2022-02-28
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors Lirilumab, Nivolumab, Ipilimumab - Advanced Cancer	Phase 1	Completed	Bristol-Myers Squibb	10	2017-07-14	2022-03-10
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer	Phase 1 / Phase 2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	472	2016-08-03	2026-07-10
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma Elotuzumab, Lirilumab, Urelumab - Multiple Myeloma	Phase 1	Completed	Bristol-Myers Squibb	44	2014-12-09	2017-11-01
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Lirilumab, Ipilimumab - CANCER, NOS	Phase 1	Completed	Bristol-Myers Squibb	22	2012-12-01	2015-07-22
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors Lirilumab, Nivolumab, Ipilimumab - CANCER,NOS	Phase 1 / Phase 2	Completed	Bristol-Myers Squibb	337	2012-10-07	2023-02-02
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma Nivolumab, Ipilimumab, Lirilumab - Non-Hodgkin's Lymphoma, Hodgkin Lymphoma	Phase 1 / Phase 2	Completed	Bristol-Myers Squibb	320	2012-08-02	2025-10-22

Conditions studied

Neoplasms (3)  ·  Multiple Myeloma (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Hodgkin Disease (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Melanoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Bristol-Myers Squibb (5)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Incyte Corporation (1)  ·  PrECOG, LLC. (1)

Countries

United States (6)  ·  France (3)  ·  Italy (3)  ·  Spain (3)  ·  Belgium (1)  ·  Canada (1)  ·  Denmark (1)  ·  Greece (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Birgit Geoerger, MD (1)  ·  Petros Grivas, MD, PhD (1)

Results publications

PMID 25482239, PMID 27269947, PMID 31538815, PMID 33892407, PMID 34347542, PMID 34543871, PMID 35292802, PMID 38155060, PMID 41838385, PMID 42686334

NIH funding

2016 (1), 2017 (1), 2018 (1)